| Sample ID |
Thalidomide [nM] |
Celecoxib [µM] |
Rapamycin [µM] |
Bevacizumab [mg/ml] |
Cetuximab [µg/ml] |
| HROG02 |
>40 |
68 |
1.0 |
>2.5 |
>20 |
| HROG04 |
>40 |
48 |
1.0 |
>2.5 |
>20 |
| HROG05 |
40 |
51 |
1.5 |
>2.5 |
>20 |
| HROG06 |
>40 |
126 |
3.0 |
>2.5 |
>20 |
| HROG07 |
>40 |
171 |
6.0 |
>2.5 |
>20 |
| HROG10 |
>40 |
74 |
6.0 |
>2.5 |
>20 |
| HROG13 |
>40 |
60 |
2.7 |
>2.5 |
>20 |
| HROG15 |
>40 |
67 |
3.0 |
>2.5 |
>20 |
| HROG17 |
0.62 |
58 |
0.4 |
>2.5 |
>20 |
| HROG24 |
>40 |
68 |
0.9 |
>2.5 |
>20 |
| HROG36 |
10.0 |
60 |
2.4 |
>2.5 |
>20 |
| HROG38 |
>40 |
68 |
31.0 |
>2.5 |
>20 |
Calculated IC50 values (after three independent assessments in triplicates) for 144 hour incubation with the therapeutic agents are provided for all cell lines |
